The Renin-Angiotensin System in the Year 2000
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Actions of Vasoactive Intestinal Peptide on the Rat Adrenal Zona Glomerulosa
51 Actions of vasoactive intestinal peptide on the rat adrenal zona glomerulosa J P Hinson, J R Puddefoot and S Kapas1 Molecular and Cellular Biology Section, Division of Biomedical Sciences, St Bartholomew’s and The Royal London School of Medicine and Dentistry, Queen Mary and Westfield College, Mile End Road, London E1 4NS, UK 1Oral Diseases Research Centre, St Bartholomew’s and The Royal London School of Medicine and Dentistry, 2 Newark Street, London E1 2AT, UK (Requests for offprints should be addressed to J P Hinson) Abstract Previous studies, by this group and others, have shown that The response to VIP in adrenals obtained from rats fed vasoactive intestinal peptide (VIP) stimulates aldosterone a low sodium diet was also investigated. Previous studies secretion, and that the actions of VIP on aldosterone have found that adrenals from animals on a low sodium secretion by the rat adrenal cortex are blocked by â diet exhibit increased responsiveness to VIP. Specific VIP adrenergic antagonists, suggesting that VIP may act by binding sites were identified, although the concentration the local release of catecholamines. The present studies or affinity of binding sites in the low sodium group was not were designed to test this hypothesis further, by measur- significantly different from the controls. In the low sodium ing catecholamine release by adrenal capsular tissue in group VIP was found to increase catecholamine release to response to VIP stimulation. the same extent as in the control group, however, in Using intact capsular tissue it was found that VIP caused contrast to the control group, the adrenal response to VIP a dose-dependent increase in aldosterone secretion, with a was not altered by adrenergic antagonists in the low concomitant increase in both adrenaline and noradrenaline sodium group. -
Still an Important Cause of Heart Failure?
Journal of Human Hypertension (2005) 19, 267–275 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh REVIEW ARTICLE Hypertension — still an important cause of heart failure? E Kazzam1, BA Ghurbana2, EN Obineche1 and MG Nicholls1 1Department of Internal Medicine, Faculty of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates; 2Department of Medicine, Al Ain Hospital, Al Ain, United Arab Emirates Hypertension has been the single most important risk from highly selected study groups in tertiary referral factor for heart failure until the last few decades. Now, it centres to patients with heart failure in primary and is frequently claimed that atherosclerotic coronary secondary care, may not be justified. Finally, the artery disease dominates as the major underlying cause, situation of heart failure primarily due to impaired left and hypertension is of lesser importance. We here ventricular diastolic function, where hypertension is a review evidence regarding the contribution of hyperten- frequent precursor, is often ignored in discussions of sion to heart failure in the recent decades. It is not aetiology. Our view is that hypertension remains and possible, in our view, to be confident of the relative probably is the single most, important modifiable risk importance of hypertension and coronary artery disease factor for cardiac failure in some races and countries, since there are significant limitations in the available where the dominant cardiac abnormality is left ventri- data. The often-questionable diagnostic criteria used in cular diastolic dysfunction. The situation is less clear for defining heart failure is one such limitation. -
Association of Hypertensive Status and Its Drug Treatment with Lipid and Haemostatic Factors in Middle-Aged Men: the PRIME Study
Journal of Human Hypertension (2000) 14, 511–518 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh ORIGINAL ARTICLE Association of hypertensive status and its drug treatment with lipid and haemostatic factors in middle-aged men: the PRIME Study P Marques-Vidal1, M Montaye2, B Haas3, A Bingham4, A Evans5, I Juhan-Vague6, J Ferrie`res1, G Luc2, P Amouyel2, D Arveiler3, D McMaster5, JB Ruidavets1, J-M Bard2, PY Scarabin4 and P Ducimetie`re4 1INSERM U518, Faculte´ de Me´decine Purpan, Toulouse, France; 2MONICA-Lille, Institut Pasteur de Lille, Lille, France; 3MONICA-Strasbourg, Laboratoire d’Epide´miologie et de Sante´ Publique, Strasbourg, France; 4INSERM U258, Hoˆ pital Broussais, Paris, France; 5Belfast-MONICA, Department of Epidemiology, The Queen’s University of Belfast, UK; 6Laboratory of Haematology, La Timone Hospital, Marseille, France Aims: To assess the association of hypertensive status this effect remained after multivariate adjustment. Cal- and antihypertensive drug treatment with lipid and hae- cium channel blockers decreased total cholesterol and mostatic levels in middle-aged men. apoproteins A-I and B; those differences remained sig- Methods and results: Hypertensive status, antihyperten- nificant after multivariate adjustment. ACE inhibitors sive drug treatment, total and high-density lipoprotein decreased total cholesterol, triglycerides, apoprotein B (HDL) cholesterol, triglyceride, apoproteins A-I and B, and LpE:B; and this effect remained after multivariate lipoparticles LpA-I, -
Angiotensin II Protocol
Angiotensin II (Giapreza ™) Protocol Background Sepsis and septic shock are medical emergencies that affect millions of people each year and killing as many as 1 in 4.1 The cornerstones of therapy are fluid resuscitation, early appropriate antibiotics, source control if needed and vasopressors. A small portion of patients fail to respond to these therapies and develop refractory shock. The definition of refractory septic shock varies in the literature but is generally considered to be hypotension, with end-organ dysfunction, requiring high-dose vasopressor support.2 The associated mortality of refractory septic shock is up to 60% and as high as 80-90% in patients requiring more than 1 mcg/kg/min of norepinephrine.2,3 Patients who develop refractory septic shock comprise a very small portion of the population in large randomized controlled trials therefore limited data is available regarding outcomes and management. Indications: Angiotensin II (Ang II) is a vasoconstrictor used to increase blood pressure in adults with septic or other distributive shock. Administration: Starting dose of 5 (nanograms) ng/kg/min intravenously via central line only. Titration: Every 5 minutes by increments of 5 ng/kg/min as needed. Maximum dose should not exceed 80 ng/kg/min (During the first 3 hours of administration); after the first 3 hours the maintenance (maximum) dose is 40 ng/kg/min. Monitoring: Critical care setting only with telemetry, arterial blood pressure, and continuous SpO2 monitoring. DVT Prophylaxis should be started (unless contraindicated) -
Pulmonary Clearance of Vasoactive Intestinal Peptide
Thorax: first published as 10.1136/thx.41.2.88 on 1 February 1986. Downloaded from Thorax 1986;41:88-93 Pulmonary clearance of vasoactive intestinal peptide MICHAEL P BARROWCLIFFE, ALYN MORICE, J GARETH JONES, PETER S SEVER From the Division ofAnaesthesia, Clinical Research Centre, Harrow, and the Department ofClinical Pharmacology and Therapeutics, St Mary's Hospital Medical School, London ABSTRACT Vasoactive intestinal peptide causes bronchodilatation when given intravenously but is less effective in both animals and man when given by inhalation. This difference may be due to poor transit of the peptide across the bronchial epithelium. To test this hypothesis pulmonary clearance of radiolabelled vasoactive intestinal peptide was measured in Sprague Dawley rats and compared with that of pertechnetate (Tc04 ) and diethylene triamine pentaacetate (DTPA). Despite a mole- cular weight (MW) of 3450, iodinated vasoactive intestinal peptide was cleared rapidly from the lungs, with a mean half time (t /2) of 19 minutes after an initial slower phase. This compares with a t'/2 of 10 minutes with Tc04 (MW 163) and a t1/2 of 158 minutes with DTPA (MW 492). The possibility that vasoactive intestinal peptide mediates a non-specific increase in permeability was discounted by the fact that the combination ofvasoactive intestinal peptide and DTPA did not alter DTPA clearance significantly. Chromatography and radioimmunoassay of blood taken after intra- tracheal administration of vasoactive intestinal peptide demonstrated a metabolite but no un- changed peptide. An intravenous injection ofthe peptide disappeared on first pass through the lung. copyright. It is concluded that inhaled vasoactive intestinal peptide lacks efficacy as a bronchodilator not because of slow diffusion to airway smooth muscle but because it is metabolised at an early stage of its passage through the respiratory epithelium. -
Role of the Renin-Angiotensin-Aldosterone
International Journal of Molecular Sciences Review Role of the Renin-Angiotensin-Aldosterone System beyond Blood Pressure Regulation: Molecular and Cellular Mechanisms Involved in End-Organ Damage during Arterial Hypertension Natalia Muñoz-Durango 1,†, Cristóbal A. Fuentes 2,†, Andrés E. Castillo 2, Luis Martín González-Gómez 2, Andrea Vecchiola 2, Carlos E. Fardella 2,* and Alexis M. Kalergis 1,2,* 1 Millenium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, 8330025 Santiago, Chile; [email protected] 2 Millenium Institute on Immunology and Immunotherapy, Departamento de Endocrinología, Escuela de Medicina, Pontificia Universidad Católica de Chile, 8330074 Santiago, Chile; [email protected] (C.A.F.); [email protected] (A.E.C.); [email protected] (L.M.G.-G.); [email protected] (A.V.) * Correspondence: [email protected] (C.E.F.); [email protected] (A.M.K.); Tel.: +56-223-543-813 (C.E.F.); +56-223-542-842 (A.M.K.) † These authors contributed equally in this manuscript. Academic Editor: Anastasia Susie Mihailidou Received: 24 March 2016; Accepted: 10 May 2016; Published: 23 June 2016 Abstract: Arterial hypertension is a common condition worldwide and an important predictor of several complicated diseases. Arterial hypertension can be triggered by many factors, including physiological, genetic, and lifestyle causes. Specifically, molecules of the renin-angiotensin-aldosterone system not only play important roles in the control of blood pressure, but they are also associated with the genesis of arterial hypertension, thus constituting a need for pharmacological interventions. Chronic high pressure generates mechanical damage along the vascular system, heart, and kidneys, which are the principal organs affected in this condition. -
Renin-Angiotensin System in Pathogenesis of Atherosclerosis and Treatment of CVD
International Journal of Molecular Sciences Review Renin-Angiotensin System in Pathogenesis of Atherosclerosis and Treatment of CVD Anastasia V. Poznyak 1,* , Dwaipayan Bharadwaj 2,3, Gauri Prasad 3, Andrey V. Grechko 4, Margarita A. Sazonova 5 and Alexander N. Orekhov 1,5,6,* 1 Institute for Atherosclerosis Research, Skolkovo Innovative Center, 121609 Moscow, Russia 2 Academy of Scientific and Innovative Research, CSIR-Institute of Genomics and Integrative Biology Campus, New Delhi 110067, India; [email protected] 3 Systems Genomics Laboratory, School of Biotechnology, Jawaharlal Nehru University, New Delhi 110067, India; [email protected] 4 Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, 14-3 Solyanka Street, 109240 Moscow, Russia; [email protected] 5 Laboratory of Angiopathology, Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia; [email protected] 6 Institute of Human Morphology, 3 Tsyurupa Street, 117418 Moscow, Russia * Correspondence: [email protected] (A.V.P.); [email protected] (A.N.O.) Abstract: Atherosclerosis has complex pathogenesis, which involves at least three serious aspects: inflammation, lipid metabolism alterations, and endothelial injury. There are no effective treatment options, as well as preventive measures for atherosclerosis. However, this disease has various severe complications, the most severe of which is cardiovascular disease (CVD). It is important to note, that CVD is among the leading causes of death worldwide. The renin–angiotensin–aldosterone system (RAAS) is an important part of inflammatory response regulation. This system contributes to Citation: Poznyak, A.V.; Bharadwaj, the recruitment of inflammatory cells to the injured site and stimulates the production of various D.; Prasad, G.; Grechko, A.V.; cytokines, such as IL-6, TNF-a, and COX-2. -
Rational Use of Beta Blockers in Management of Hypertension Khawaja Tahir Mehmood, Fatima Amin, Hafiza Kiran Ismail, Ayesha Irfan
Khawaja Tahir Mahmood et al /J. Pharm. Sci. & Res. Vol.3(1), 2011,1029-1034 Rational Use of Beta Blockers in Management of Hypertension Khawaja Tahir Mehmood, Fatima Amin, Hafiza Kiran Ismail, Ayesha Irfan. Lahore College for women university Lahore, Pakistan Abstract: Hypertension is an extremely common disorder. It is major risk factor for cardiovascular morbidity and mortality through its effects on target organs like brain heart kidney eyes. In Pakistan magnitude of problem of uncontrolled hypertension is greater. .Treatment of hypertension decreases morbidity and increases life expectancy. Beta blockers are widely used in the treatment of hypertension. Beta blockers are effective only when they are rationally prescribed and used. It is retrospective type of study during which data of 50 hypertensive patients with primary hypertension using beta blockers were collected to analyze whether beta blockers are rationally prescribed and used. After therapy with beta blockers Blood pressure is effectively controlled. After the therapy 20 % patient have B.P in range of 110-130, 56% patients have B.P in range of 120- 130 and 24% have B.P in range of 130-140.It is concluded that blood pressure is effectively controlled when beta blockers rationally used. It should be given with caution in older and diabetic patients because it increases the risk of stroke in older patients. It is most effective when given in combination. Key words; Beta blockers, Hypertension, rational use, INTRODUCTION: systolic hypertension, white coat hypertension Hypertension is defined as either a sustained and resistant hypertension. (5, 6) systolic blood pressure of greater than 140 Although exact causes of primary hypertension mmHg or sustained diastolic blood pressure of is not fully understood it is known that some greater than 90mmHg. -
Five Decades of Research on Opioid Peptides: Current Knowledge and Unanswered Questions
Molecular Pharmacology Fast Forward. Published on June 2, 2020 as DOI: 10.1124/mol.120.119388 This article has not been copyedited and formatted. The final version may differ from this version. File name: Opioid peptides v45 Date: 5/28/20 Review for Mol Pharm Special Issue celebrating 50 years of INRC Five decades of research on opioid peptides: Current knowledge and unanswered questions Lloyd D. Fricker1, Elyssa B. Margolis2, Ivone Gomes3, Lakshmi A. Devi3 1Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA; E-mail: [email protected] 2Department of Neurology, UCSF Weill Institute for Neurosciences, 675 Nelson Rising Lane, San Francisco, CA 94143, USA; E-mail: [email protected] 3Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, Annenberg Downloaded from Building, One Gustave L. Levy Place, New York, NY 10029, USA; E-mail: [email protected] Running Title: Opioid peptides molpharm.aspetjournals.org Contact info for corresponding author(s): Lloyd Fricker, Ph.D. Department of Molecular Pharmacology Albert Einstein College of Medicine 1300 Morris Park Ave Bronx, NY 10461 Office: 718-430-4225 FAX: 718-430-8922 at ASPET Journals on October 1, 2021 Email: [email protected] Footnotes: The writing of the manuscript was funded in part by NIH grants DA008863 and NS026880 (to LAD) and AA026609 (to EBM). List of nonstandard abbreviations: ACTH Adrenocorticotrophic hormone AgRP Agouti-related peptide (AgRP) α-MSH Alpha-melanocyte stimulating hormone CART Cocaine- and amphetamine-regulated transcript CLIP Corticotropin-like intermediate lobe peptide DAMGO D-Ala2, N-MePhe4, Gly-ol]-enkephalin DOR Delta opioid receptor DPDPE [D-Pen2,D- Pen5]-enkephalin KOR Kappa opioid receptor MOR Mu opioid receptor PDYN Prodynorphin PENK Proenkephalin PET Positron-emission tomography PNOC Pronociceptin POMC Proopiomelanocortin 1 Molecular Pharmacology Fast Forward. -
The Role of Corticotropin-Releasing Hormone at Peripheral Nociceptors: Implications for Pain Modulation
biomedicines Review The Role of Corticotropin-Releasing Hormone at Peripheral Nociceptors: Implications for Pain Modulation Haiyan Zheng 1, Ji Yeon Lim 1, Jae Young Seong 1 and Sun Wook Hwang 1,2,* 1 Department of Biomedical Sciences, College of Medicine, Korea University, Seoul 02841, Korea; [email protected] (H.Z.); [email protected] (J.Y.L.); [email protected] (J.Y.S.) 2 Department of Physiology, College of Medicine, Korea University, Seoul 02841, Korea * Correspondence: [email protected]; Tel.: +82-2-2286-1204; Fax: +82-2-925-5492 Received: 12 November 2020; Accepted: 15 December 2020; Published: 17 December 2020 Abstract: Peripheral nociceptors and their synaptic partners utilize neuropeptides for signal transmission. Such communication tunes the excitatory and inhibitory function of nociceptor-based circuits, eventually contributing to pain modulation. Corticotropin-releasing hormone (CRH) is the initiator hormone for the conventional hypothalamic-pituitary-adrenal axis, preparing our body for stress insults. Although knowledge of the expression and functional profiles of CRH and its receptors and the outcomes of their interactions has been actively accumulating for many brain regions, those for nociceptors are still under gradual investigation. Currently, based on the evidence of their expressions in nociceptors and their neighboring components, several hypotheses for possible pain modulations are emerging. Here we overview the historical attention to CRH and its receptors on the peripheral nociception and the recent increases in information regarding their roles in tuning pain signals. We also briefly contemplate the possibility that the stress-response paradigm can be locally intrapolated into intercellular communication that is driven by nociceptor neurons. -
Comparison of Effectiveness and Safety of Labetalol and Hydralazine on Blood Pressure During Cataract Surgery in Patients with Hypertensio
Revista Latinoamericana de Hipertensión ISSN: 1856-4550 [email protected] Sociedad Latinoamericana de Hipertensión Venezuela Comparison of effectiveness and safety of labetalol and hydralazine on blood pressure during cataract surgery in patients with hypertensio Espahbodi, Ebrahim; Takzare, Alireza; Sanatkar, Mehdi; Goudarzi, Mehrdad Comparison of effectiveness and safety of labetalol and hydralazine on blood pressure during cataract surgery in patients with hypertensio Revista Latinoamericana de Hipertensión, vol. 14, no. 4, 2019 Sociedad Latinoamericana de Hipertensión, Venezuela Available in: https://www.redalyc.org/articulo.oa?id=170263002018 Derechos reservados. Queda prohibida la reproducción total o parcial de todo el material contenido en la revista sin el consentimiento por escrito del editor en jefe. Copias de los artículos: Todo pedido de separatas deberá ser gestionado directamente con el editor en jefe, quien gestionará dicha solicitud ante la editorial encargada de la publicación. This work is licensed under Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International. PDF generated from XML JATS4R by Redalyc Project academic non-profit, developed under the open access initiative Revista Latinoamericana de Hipertensión, 2019, vol. 14, no. 4, ISSN: 1856-4550 Artículos Comparison of effectiveness and safety of labetalol and hydralazine on blood pressure during cataract surgery in patients with hypertensio Comparación de la efectividad y la seguridad de labetalol e hidralazina en la presión arterial -
Secretion, Degradation, and Elimination of Glucagon-Like
Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects Juris J. Meier,1 Michael A. Nauck,1,2 Daniel Kranz,1 Jens J. Holst,3 Carolyn F. Deacon,3 Dirk Gaeckler,4 Wolfgang E. Schmidt,1 and Baptist Gallwitz1 CRI patients vs. healthy control subjects, respectively. ؎ ؎ Glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) are important factors in the patho- Plasma half-lives of intact GIP were 6.9 1.4 and 5.0 ؎ ؎ ؍ genesis of type 2 diabetes and have a promising thera- 1.2 min (P 0.31) and 38.1 6.0 and 22.4 3.0 min for ؍ peutic potential. Alterations of their secretion, in vivo the GIP metabolite (P 0.032) for CRI patients vs. degradation, and elimination in patients with chronic healthy control subjects, respectively. Insulin concen- renal insufficiency (CRI) have not yet been character- trations tended to be lower in the patients during all ized. Ten patients with CRI (aged 47 ؎ 15 years, BMI experiments, whereas C-peptide levels tended to be kg/m2, and serum creatinine 2.18 ؎ 0.86 elevated. These data underline the importance of the 2.2 ؎ 24.5 mg/dl) and 10 matched healthy control subjects (aged kidneys for the final elimination of GIP and GLP-1. The years, BMI 24.9 ؎ 3.4 kg/m2, and serum creati- initial dipeptidyl peptidase IV–mediated degradation of 12 ؎ 44 nine 0.89 ؎ 0.10 mg/dl) were included. On separate both hormones is almost unaffected by impairments in occasions, an oral glucose tolerance test (75 g), an renal function.